Role of Epoxy-eicosatrienoic Acids in Post-occlusive Hyperemia and Thermal Hyperemia

Overview

The objective of this proof of concept study is to assess the involvement of epoxy-eicosatrienoic acids (EETs) in post-occlusive hyperemic and thermal hyperemia responses, and the interaction between nitric oxide (NO) and EETs, using the latest methods for the study of functional microcirculation.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2012

Detailed Description

The EETY study is a single-center proof of concept study in healthy volunteers. The main objective is to study the involvement of epoxy-eicosatrienoic acids (EETs) in the reactivity of cutaneous microcirculation during post-occlusive hyperemia and thermal hyperemia, by studying the response to microdialysis of fluconazole (an inhibitor of EETs) versus control, on the forearm. Response is measured by the amplitude of the post-occlusive hyperemia and thermal hyperemia peaks (maximum amplitude as a percentage of maximal vasodilation and areas under the curve: AUC) during the injection of fluconazole compared to an intradermal injection of solvent (NaCl 9 ‰). The subjects are healthy volunteers of both sexes, aged between 18 and 35, non-smokers and in good health. Over two years, 30 subjects will be included in the study for 6 to 13 weeks.

Interventions

  • Drug: Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)
    • At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.

Arms, Groups and Cohorts

  • Placebo Comparator: Vehicle without ANESDERM (lidocaine, prilocaine)
  • Active Comparator: Vehicle with ANESDERM (lidocaine, prilocaine)
  • Active Comparator: Fluconazole without ANESDERM (lidocaine, prilocaine)
  • Active Comparator: Fluconazole with ANESDERM (lidocaine, prilocaine)

Clinical Trial Outcome Measures

Primary Measures

  • Amplitude of the post-occlusive hyperemia and thermal hyperemia following the injection by intradermal microdialysis of fluconazole compared with injection of vehicle (NaCl 9 ‰)
    • Time Frame: 2 hours
    • maximum amplitude as a percentage of maximal vasodilation and area under the curve: AUC

Secondary Measures

  • Amplitude of the post-occlusive hyperemia and thermal hyperemia following the injection by intradermal microdialysis of fluconazole, at 2 concentrations, or vehicle (NaCl 9 ‰)
    • Time Frame: 2 hours
    • maximum amplitude expressed as percentage of maximal vasodilation and AUC
  • Amplitude of the post-occlusive hyperemia and thermal hyperemia following the injection by intradermal microdialysis of fluconazole or vehicle (NaCl 9 ‰), with and without ANESDERM ® (lidocaine, prilocaine)
    • Time Frame: 2 hours
    • maximum amplitude expressed as percentage of maximal vasodilation and AUC
  • Amplitude of the post-occlusive hyperemia and thermal hyperemia following the injection by intradermal microdialysis of fluconazole or vehicle (NaCl 9 ‰), with and without N(G)-nitro-L-arginine-methyl ester (L-NMMA)
    • Time Frame: 2 hours
    • maximum amplitude expressed as percentage of maximal vasodilation and AUC

Participating in This Clinical Trial

Inclusion Criteria

  • Age between 18 and 35 years – Affiliated to the French social security system or beneficiary a similar regime – In good health Exclusion Criteria:

  • Active smoker – Pregnant, parturient, breast-feeding – Person deprived of civil liberties by judicial or administrative measure; person under legal protection, – Minor less than 18 years – Within period exclusion for other clinical research studies – Person has exceeded the annual compensation for participation in trials – Person with active disease or with prolonged treatment, excluding oral contraceptives and paracetamol – Asthma, urticaria, angioedema, known drug allergy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 35 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University Hospital, Grenoble
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jean-Luc Cracowski, MD,PhD, Principal Investigator, University Hospital, Grenoble

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.